Commentary Open Access
Volume 1 | Issue 1 | DOI: https://doi.org/10.46439/ophthalmology.1.003
How many mutations does it take to make a uveal melanoma?
Francesca Piaggio1, Veronica Tozzo2, Cinzia Bernardi1, Michela Croce3, Claudia Lo Sicco1, Rosaria Gangemi3, Roberto Puzone4, Silvia Viaggi5,6, Serena Patrone6, Annalisa Barla2, Domenico Coviello6, Martine J. Jager7, Pieter A. van der Velden7, Davide Cangelosi8, Alessandra Eva8, Silvano Ferrini3, Ulrich Pfeffer1,*, Adriana Amaro1
- 1Tumor Epigenetics, IRCCS Ospedale Policlinico San Martino, Genova, Italy
- 2DIBRIS, University of Genova, Italy
- 3Biotherapy, IRCCS Ospedale Policlinico San Martino, Genova Italy
- 4Clinical Epidemiology, IRCCS Ospedale Policlinico San Martino, Genova, Italy
- 5DISTAV, University of Genova, Italy
- 6IRCCS Istituto G. Gaslini, Genova, Italy
- 7Department of Ophthalmology, Leiden University Medical Center, Leiden, The Netherlands
- 8Laboratory of Molecular Biology, IRCCS Istituto Giannina Gaslini, Genova, Italy
Corresponding Author
Ulrich Pfeffer, ulrich.pfeffer@cliffordchance.com
Received Date: December 13, 2019
Accepted Date: December 28, 2019
Piaggio F, Tozzo V, Bernardi C, Croce M, Sicco CL, Gangemi R, et al. How many mutations does it take to make a uveal melanoma? Arch Clin Exp Ophthalmol 2019; 1(1):6-11.
Copyright: © 2019 Piaggio F, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Recommended Articles
How many mutations does it take to make a uveal melanoma?
Uveal melanoma (UM) is a rare cancer that affects the choroid and, less frequently, the ciliary body or the iris (for recent reviews see [1-3]). Despite a profound knowledge of the oncogenic mechanisms behind UM tumorigenesis and despite an accurate cytogenetic and molecular prognosis, only limited advances have been made in UM therapy.
Genetic mutations in the molecular pathogenesis of gastrointestinal stromal tumor
Gastrointestinal stromal tumors are mesenchymal tumors which predominantly originate from the interstitial cells of Cajal in the intestinal lining. Around ~85% of malignant GISTs possess activating mutations in the tyrosine kinase receptors KIT or PDGFRA. The driver mutations in genes other than KIT or PDGFRA account for around 15% GISTs and belong to highly heterogeneous groups called wild-type GISTs. Around 20–40% of WT-GISTS are deficient for the succinate dehydrogenase complex (SDHA, SDHB, SDHC, SDHD).
Omics analysis of uveal melanoma: Leukocyte gene signatures reveal novel survival distinctions and indicate a prognostic role for cytolytic activity scoring
The significant metastatic potential of uveal melanoma (UVM) lends to high mortality. Even with successful local tumor treatment, many patients will develop metastatic disease. The present study aims to elucidate the relationship between tumor-infiltrating immune cell (TIIC) diversity and survival to identify potential therapeutic targets and improve UVM prognosis.
Oncogenic specificity in nevus and melanoma formation
There is striking clinical, histological, and molecular diversity observed across melanocytic tumors. Activating mutations in BRAF and NRAS are well-established initiators of benign melanocytic nevi and melanoma. However, accumulating evidence reveals that the biological outcome after oncogene activation is dependent on cellular state differences that vary by anatomic site, developmental timing, and cell of origin.
Injectable hydrogel of biopolymers as controlled drug-delivery vehicle for melanoma treatment: A commentary
Melanoma is a strongly incursive cancer situated in the skin with narrow consecutive therapies. The goal of this article is to reveal some of the latest advances in using hydrogel for cancer especially melanoma therapy. Biocompatible brush biopolymer (linear dextrin) graft with polyurethane is developed for monitoring the hydrophilic and hydrophobic equipoise for regulating the delivery of drug to the target region. Drug incorporated brush copolymers upon embedded in gelating agent (methyl cellulose) develop an injectable hydrogel with potential